Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Idexx Laboratories ( (IDXX) ) has provided an announcement.
On October 6, 2025, IDEXX Laboratories elected Karen Peacock as an independent Class I Director and appointed her to its Compensation and Talent Committee and Finance Committee. This strategic addition to the board is expected to enhance the company’s leadership with Peacock’s extensive experience in B2B, SaaS software, and AI, potentially strengthening IDEXX’s position in the pet healthcare industry.
The most recent analyst rating on (IDXX) stock is a Buy with a $745.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.
Spark’s Take on IDXX Stock
According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.
Idexx Laboratories demonstrates strong financial performance and positive earnings call sentiment, driving a high overall score. Technical indicators support a bullish outlook, although the high P/E ratio suggests the stock is expensive. The company’s strategic focus on international markets and innovation positions it well for future growth.
To see Spark’s full report on IDXX stock, click here.
More about Idexx Laboratories
IDEXX Laboratories, Inc., headquartered in Maine, is a global leader in pet healthcare innovation, offering diagnostic and software products and services that enhance veterinary medicine. The company supports veterinary practices worldwide, ensuring the safety of milk and water, and employs approximately 11,000 people across more than 175 countries.
Average Trading Volume: 545,210
Technical Sentiment Signal: Buy
Current Market Cap: $50.23B
For a thorough assessment of IDXX stock, go to TipRanks’ Stock Analysis page.